{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T21:50:32Z","timestamp":1724968232657},"reference-count":18,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2009,2,9]],"date-time":"2009-02-09T00:00:00Z","timestamp":1234137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2009,3]]},"abstract":"<jats:sec><jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Post\u2010marketing surveillance studies (PMSS) of medications are often mandated by authorities, provide crucial insights for health services and are useful to define the clinical profiles of therapies. Desloratadine, a non\u2010sedating, second\u2010generation H<jats:sub>1<\/jats:sub>\u2010receptor antagonist, is an effective and well\u2010tolerated treatment for chronic idiopathic urticaria (CIU).<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> A PMSS in CIU patients evaluated the tolerability and efficacy of desloratadine in clinical practice. At Visit 1 (baseline), demographic and CIU history were recorded and patients\/physicians rated the severity of CIU symptoms, interference with sleep\/daily activities and the general state of urticaria. Patients also noted the use and effectiveness of previous antihistamine therapy. At the end of treatment (Visit 2), CIU symptom severity and other disease criteria were re\u2010assessed. Adverse events reported during or \u2264\u00a030\u00a0days after treatment were collected.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> A total of 9246 patients with CIU participated (63% female). Itching, number of wheals and the size of the largest wheal decreased significantly from baseline with desloratadine therapy (<jats:italic>P\u00a0&lt;<\/jats:italic>\u00a00.0001). Improvements in CIU\u2010impaired sleep and daily activities were reported by 67% and 71% of patients, respectively (<jats:italic>P\u00a0&lt;<\/jats:italic>\u00a00.0001). In patients that received previous therapy with cetirizine, loratadine or fexofenadine alone, patients rated the onset of efficacy of desloratadine as faster in 55.5%, 54.7% and 57.6% of cases, respectively. The incidence of adverse events was low (0.5% of patients) and no serious adverse events were reported.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> This large PMSS confirms evidence from multiple placebo\u2010controlled trials that desloratadine is effective and well tolerated in the treatment of CIU.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conflicts of interest<\/jats:title><jats:p>None declared<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-3083.2008.03034.x","type":"journal-article","created":{"date-parts":[[2009,2,10]],"date-time":"2009-02-10T04:39:46Z","timestamp":1234240786000},"page":"292-299","source":"Crossref","is-referenced-by-count":17,"title":["Safety and efficacy of desloratadine in chronic idiopathic urticaria in clinical practice: an observational study of 9246 patients"],"prefix":"10.1111","volume":"23","author":[{"given":"M","family":"Augustin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Ehrle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,2,9]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2007.00276.x"},{"key":"e_1_2_5_3_2","first-page":"214","article-title":"Epidemiology of urticaria in Spain","volume":"14","author":"Gaig P","year":"2004","journal-title":"J Invest Allergol Clin Immunol"},{"key":"e_1_2_5_4_2","first-page":"181","article-title":"[Prevalence and potential triggering factors of chronic urticaria and angioedema in an urban area of northeastern Mexico.]","volume":"51","author":"V\u00e1zquez Nava F","year":"2004","journal-title":"Rev Alerg Mex"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)60617-5"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06976.x"},{"key":"e_1_2_5_7_2","doi-asserted-by":"crossref","first-page":"196","DOI":"10.2340\/00015555-0240","article-title":"Urticaria: current opinions about etiology, diagnosis and therapy","volume":"87","author":"Zuberbier T","year":"2007","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2005.00964.x"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2005.00962.x"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2001.00186.x"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.143"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200708010-00005"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2007.02385.x"},{"key":"e_1_2_5_14_2","first-page":"247","article-title":"Empfehlungen zur Durchf\u00fchrung von Anwendungsbeobachtungen","volume":"28","author":"Victor N","year":"1997","journal-title":"Informatik Biometrie Epidemiologie Med Biologie"},{"key":"e_1_2_5_15_2","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukt: Gemeinsame Empfehlungen des Bundesinstituts f\u00fcr Arzneimittel und Medizinprodukte und des Paul\u2010Ehrlich\u2010Instituts zur Planung Durchf\u00fchrung und Auswertung von Anwendungsbeobachtungen Entwurfsfassung vom 9.Mai 2007."},{"issue":"2","key":"e_1_2_5_16_2","first-page":"43\/52","article-title":"Desloratadine in the treatment of seasonal allergic rhinitis: results of a large observational study","volume":"22","author":"Bachert C","year":"2002","journal-title":"Clin Drug Invest"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2006.01429.x"},{"key":"e_1_2_5_18_2","first-page":"547","article-title":"Desloratadine for chronic idiopathic urticaria","volume":"144","author":"Rottem M","year":"2005","journal-title":"Harefuah"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.06.018"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2008.03034.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2008.03034.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T12:58:00Z","timestamp":1696942680000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2008.03034.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,9]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["10.1111\/j.1468-3083.2008.03034.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2008.03034.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,9]]}}}